Population pharmacokinetics of paracetamol across the human age-range from (pre)term neonates, infants, children to adults

J Clin Pharmacol. 2014 Jun;54(6):619-29. doi: 10.1002/jcph.259. Epub 2014 Jan 23.

Abstract

In order to characterize the variation in pharmacokinetics of paracetamol across the human age span, we performed a population pharmacokinetic analysis from preterm neonates to adults with specific focus on clearance. Concentration-time data obtained in 220 neonates (post-natal age 1-76 days, gestational age 27-42 weeks), infants (0.11-1.33 yrs), children (2-7 yrs) and adults (19-34 yrs) were analyzed using NONMEM 7.2. In the covariate analysis, linear functions, power functions, and a power function with a bodyweight-dependent exponent were tested. Between preterm neonates and adults, linear bodyweight functions were identified for Q2, Q3, V1, V2, and V3, while for CL a power function with a bodyweight-dependent exponent k was identified (CLi = CLp × (BW/70)(k) ). The exponent k was found to decrease in a sigmoidal manner with bodyweight from 1.2 to 0.75, with half the decrease in exponent reached at 12.2 kg. No other covariates such as age were identified. A pharmacokinetic model for paracetamol characterizing changes in pharmacokinetic parameters across the pediatric age-range was developed. Clearance was found to change in a nonlinear manner with bodyweight. Based on the final model, dosing guidelines are proposed from preterm neonates to adolescents resulting in similar exposure across all age ranges.

Keywords: allometry; clearance; paracetamol; pediatric; pharmacokinetics.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetaminophen / pharmacokinetics*
  • Adult
  • Aging / metabolism
  • Analgesics, Non-Narcotic / pharmacokinetics*
  • Child
  • Child, Preschool
  • Humans
  • Infant
  • Infant, Newborn
  • Infant, Premature
  • Male
  • Models, Biological*
  • Young Adult

Substances

  • Analgesics, Non-Narcotic
  • Acetaminophen